🇺🇸 FDA
Pipeline program

PARACETAMOL, DIPHENHYDRAMINE, INFLIXIMAB, TOCILIZUMAB, AZD7789, EPINEPHRINE

D9571C00001

Phase 2 small_molecule active

Quick answer

PARACETAMOL, DIPHENHYDRAMINE, INFLIXIMAB, TOCILIZUMAB, AZD7789, EPINEPHRINE for Relapsed/Refractory Classical Hodgkin Lymphoma is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Relapsed/Refractory Classical Hodgkin Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials